Abstract | BACKGROUND: METHODS: RESULTS: The incidence of delayed graft function did not significantly differ between the cohorts (10% and 13%, in basiliximab and control group). Significantly fewer patients in the basiliximab group had acute rejection episodes (20% vs. 36% in control group, P=0.007). The mean estimated glomerular filtration rate at 1 year and graft survival at 2 years posttransplant did not differ between groups (62 vs. 64 mL/min 1.73 m2, and 89% vs. 92%, respectively). CONCLUSION:
|
Authors | Karlien Cransberg, Antonia H Bouts, Elisabeth A M Cornelissen, Marc R Lilien, Koen J Van Hoeck, Wim C J Hop, Jeroen Nauta |
Journal | Transplantation
(Transplantation)
Vol. 86
Issue 9
Pg. 1199-205
(Nov 15 2008)
ISSN: 1534-6080 [Electronic] United States |
PMID | 19005400
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Adrenal Cortex Hormones
- Antibodies, Monoclonal
- Immunosuppressive Agents
- Recombinant Fusion Proteins
- Cyclosporine
- Basiliximab
- Creatinine
- Mycophenolic Acid
|
Topics |
- Adolescent
- Adrenal Cortex Hormones
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Basiliximab
- Child
- Child, Preschool
- Cohort Studies
- Controlled Clinical Trials as Topic
- Creatinine
(blood)
- Cyclosporine
(therapeutic use)
- Drug Therapy, Combination
- Glomerular Filtration Rate
(physiology)
- Graft Rejection
(prevention & control)
- Graft Survival
(physiology)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Kidney Transplantation
(immunology, physiology)
- Multivariate Analysis
- Mycophenolic Acid
(analogs & derivatives, therapeutic use)
- Recombinant Fusion Proteins
(therapeutic use)
- Recovery of Function
(physiology)
- Retrospective Studies
- Time Factors
|